Back

Seed Capital

Get Deal Flow

Salus

SAL

Lead Manager

Contact - Joanne Hannah

0477 834 834

jo@salusaus.com.au

Minimum Investment

A$5,000

Express Interest Ask the Company

Express Interest

Back

Seed Capital

Get Deal Flow

Salus presents an opportunity to invest in the highly successful medical aesthetic sector which offers high-growth potential driven by soaring demand for non-surgical cosmetic treatments.

Salus is a vertically integrated, medical subscription platform generating recurring revenue through product sales, clinical training programs, and prescribing support services. Built with regulatory compliance at its core, Salus delivers high-margin, multi-channel income streams while reducing operational risk and strengthening long-term customer value.

Offer Details

Issue Price (Per Share)

A$1.000

Offer Size

A$300,000

Shares Available

300,000

Salus is raising $300,000 in growth equity at a valuation of $2,000,000.

Documents & Downloads

Salus Investor Deck

Company Overview

Salus is a Western Australia–based aesthetic partner group focused on supporting and future-proofing cosmetic clinics and healthcare practitioners. The business operates a proprietary digital platform and app designed to enhance patient safety by connecting consumers with competent, compliant, and outcome-focused providers.

Salus delivers end-to-end digital workflows that streamline prescribing, product ordering, and practitioner training while ensuring full regulatory compliance. These systems reduce operational friction for clinics and enable prescribers to operate efficiently within a robust governance framework.

The company is led by a industry-experienced team that provides responsive, local medical governance and ongoing support, positioning Salus as a trusted infrastructure partner to the aesthetics sector.

The Four Pillars

The Australian Non-Surgical Aesthetic Market

The WA market value is estimated at $400m plus.

Spending

Australians currently spend an estimated $2.6bn on cosmetic injectable treatments. This is growing steadily at 12.3% per year.

Professionals

70% of injectable treatments are administered by nurses, with the rest provided by plastic surgeons, dermatologists, GPs, and dentists. Only AHPRA registered medical practitioners can perform these treatments, which must occur in a medical facility in Western Australia.

WA

About 8.2% of Australia's market is in Western Australia, where cosmetic practice support systems are inadequate. There is a need for a group to provide local, immediate support to clinicians.

Accelerating Member Acquisition

Established supplier agreements with favorable terms to ensure competitive member pricing.
Launched member-exclusive Prescribing App for compliant and efficient prescribing.
Member ordering portal now features 100+ products, including S4 medications and consumables, with updated pricing and specials.
Provided clinical training solutions through the medical team for members.
Delivered compliance updates from AHPRA and the Department of Health on medications.

Salus are currently establishing and refining their first cohort of members, aiming for readiness in Q1 2026 to enter our growth phase.

Salus Growth Journey

Growth phase 1

Steady controlled growth from 10 to 120+ members
In person support
Ensuring detailed review of processes, policies and procedures.
Focus on regulatory guidelines and best practice
Detailed, appropriate consults by WA based prescribers.
Working with suppliers to provide training programs that cater to specific needs of the WA market.
Salus talent acquisition
Collaboration with CNA & AMET

Consolidation

Launch Salus Training Academy
Salus inaugural conference
Draw on experience of founding members to refine support
Collaboration with suppliers to provide improved training opportunities by skill level
Launch rewards program and education credits
Develop prescribing team
Review of technology and practice integration
Working with pharma suppliers to increase intimate training sessions (small groups)
MAC review of first 12 months of operation

Growth Phase 2

Having refined protocol and practice guidelines, strong emphasis on recruitment
Growth of strategic partnerships
Working with leading suppliers to expand training offering
Expansion across the state (hubs in regional centres)
- Bunbury, Geraldton, Albany and Kalgoorlie locations / partner clinics
- Mobile training teams for Busselton, Karratha, Port Hedland, Broome.
Increasing trainers within the membership

Optimisation

Sophisticated skillset across executive, MAC and faculty
Support of metro and regional clinicians through multiple centres throughout all of WA Training programs and conference schedule established in the industry
Membership numbers to expand beyond 450
Strategic expansion of business offerings Brand accelerator potential for new products

Use of Funds

Tech Development; Prescribing app, e-commerce and member portal

$60,000.00

20%

Member engagement and onboarding

$55,000.00

18.33%

Compliance, scientific and regulatory

$35,000.00

11.67%

Working Capital

$150,000.00

50%

Total

$300,000.00

100%

Tech Development; Prescribing app, e-commerce and member portal

$60,000.00

20%

Member engagement and onboarding

$55,000.00

18.33%

Compliance, scientific and regulatory

$35,000.00

11.67%

Working Capital

$150,000.00

50%

Total

$300,000.00

100%

Board & Mangement

Dr Jane Lucas

Medical Director

Dr Jane Lucas is a highly experienced, full time cosmetic physician, director of Coco Skin Clinics in Perth and industry KOL.

Jane completed her Bachelor of Medicine, Bachelor of Surgery at The University of Western Australia (UWA) in 2005, holds Specialist Fellowship in General Practice and is a Fellow of the Australasian College of Aesthetic Medicine.

Joanne Hannah

CEO

Jo started her aesthetic career in 2010 with Allergan and has had an un-rivalled, diverse career path encompassing all aspects of the aesthetic industry.

As CEO of Total Face Group, the sectors first ASX listed company, Jo has valuable experience in M&A, governance and compliance, scalable solutions and growth strategies. Jo is also Director and owner of Hannah Aesthetics.

Kylie Smith

Clinical Director

Kylie Smith is a well-respected senior cosmetic injector with over 20 years injectable experience.

Kylie is the Director and owner of the Naturaliste Skin Clinics located in Busselton, Dunsborough and Bunbury and an experienced industry trainer and mentor.

Disclaimer

This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of Salus. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.

Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in Salus.

Salus

Salus

Offer Details

Documents & Downloads

Company Overview

The Four Pillars